New Directions in Imaging Neuroendocrine Neoplasms.
CCK2-receptor imaging
GLP-1 receptor imaging
Neuroendocrine neoplasms
Peptide hormone receptors
Somatostatin receptor antagonist
Journal
Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967
Informations de publication
Date de publication:
04 11 2021
04 11 2021
Historique:
accepted:
05
04
2021
entrez:
4
11
2021
pubmed:
5
11
2021
medline:
19
2
2022
Statut:
epublish
Résumé
Accurate imaging is crucial for correct diagnosis, staging, and therapy of neuroendocrine neoplasms (NENs). The search for the optimal imaging technique has triggered rapid development in the field. This review aims at giving an overview on contemporary imaging methods and providing an outlook on current progresses. The discovery of molecular targets due to the overexpression of specific peptide hormone receptors on the NEN's surface has triggered the development of multiple radionuclide imaging modalities. In addition to the established imaging technique of targeting somatostatin receptors, several alternative radioligands have been developed. Targeting the glucagon-like peptide-1 receptor by exendin-4 has a high sensitivity in localizing insulinomas. For dedifferentiated NENs, new molecular targets such as the C-X-C motif chemokine-receptor-4 have been evaluated. Other new targets involve the fibroblast activation protein and the cholecystokinin-2 receptors, where the ligand minigastrin opens new possibilities for the management of medullary thyroid carcinoma. Molecular imaging is an emerging field that improves the management of NENs.
Identifiants
pubmed: 34735669
doi: 10.1007/s11912-021-01139-2
pii: 10.1007/s11912-021-01139-2
pmc: PMC8568754
doi:
Substances chimiques
Peptides
0
Receptors, Cholecystokinin
0
Receptors, Somatostatin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
143Informations de copyright
© 2021. The Author(s).
Références
Pancreas. 2017 Jul;46(6):715-731
pubmed: 28609357
J Nucl Med. 2009 Jun;50(6):858-64
pubmed: 19443590
Q J Nucl Med Mol Imaging. 2010 Feb;54(1):68-75
pubmed: 20168288
J Nucl Med. 2007 Apr;48(4):508-18
pubmed: 17401086
Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):943-66
pubmed: 23417499
J Clin Endocrinol Metab. 2017 Jan 1;102(1):195-199
pubmed: 27805844
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Oncologist. 2018 Feb;23(2):186-192
pubmed: 29118267
J Nucl Med. 2014 Nov;55(11):1786-90
pubmed: 25286923
J Clin Oncol. 2016 Feb 20;34(6):588-96
pubmed: 26712231
Eur Radiol. 2015 Mar;25(3):751-9
pubmed: 25447971
Radiology. 2010 Mar;254(3):765-73
pubmed: 20177091
Theranostics. 2017 Apr 5;7(6):1489-1498
pubmed: 28529632
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16436-41
pubmed: 17056720
PET Clin. 2008 Oct;3(4):577-85
pubmed: 27156821
BMC Cancer. 2020 Apr 16;20(1):326
pubmed: 32299391
Radiology. 2016 May;279(2):420-31
pubmed: 26599801
Neuroendocrinology. 2017 Feb 11;105(3):196-200
pubmed: 28190015
Ann Oncol. 2015 Aug;26(8):1604-20
pubmed: 25646366
Ann Nucl Med. 2017 Jun;31(5):357-365
pubmed: 28349331
Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1431-8
pubmed: 18418596
Lancet Diabetes Endocrinol. 2013 Oct;1(2):115-22
pubmed: 24622317
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2112-2137
pubmed: 31254038
Oncotarget. 2016 Feb 23;7(8):9288-95
pubmed: 26843617
Nucl Med Mol Imaging. 2015 Jun;49(2):143-51
pubmed: 26085860
AJR Am J Roentgenol. 2003 Jan;180(1):121-8
pubmed: 12490490
Acta Radiol. 2014 May;55(4):389-98
pubmed: 23928010
Eur Radiol. 2019 Dec;29(12):6880-6890
pubmed: 31227882
Rev Endocr Metab Disord. 2021 Sep;22(3):581-594
pubmed: 32495250
J Nucl Med. 2015 Jun;56(6):847-54
pubmed: 25952736
J Thorac Oncol. 2020 Oct;15(10):1577-1598
pubmed: 32663527
AJR Am J Roentgenol. 2010 Mar;194(3):629-33
pubmed: 20173138
JAMA Oncol. 2017 Oct 1;3(10):1335-1342
pubmed: 28448665
J Nucl Med. 2014 Jun;55(6):976-82
pubmed: 24744444
Contrast Media Mol Imaging. 2018 Feb 26;2018:2340389
pubmed: 29681780
J Clin Oncol. 2005 Jan 1;23(1):70-8
pubmed: 15625361
Clin Nucl Med. 2017 Jul;42(7):525-529
pubmed: 28481789
Radiology. 1998 Jul;208(1):181-5
pubmed: 9646811
Radiology. 2015 Mar;274(3):712-22
pubmed: 25286324
J Nucl Med. 2018 Jun;59(6):915-921
pubmed: 29191855
Endocr Relat Cancer. 2018 Mar;25(3):R115-R130
pubmed: 29233841
Neuroendocrinology. 2022;112(2):143-152
pubmed: 33508821
Cancer Imaging. 2018 Oct 17;18(1):37
pubmed: 30333055
J Nucl Med. 2016 May;57(5):708-14
pubmed: 26769865
N Engl J Med. 2008 Aug 14;359(7):766-8
pubmed: 18703486
J Nucl Med. 2013 Dec;54(12):2032-8
pubmed: 24101685
Acad Radiol. 2010 Mar;17(3):291-7
pubmed: 19962915
J Nucl Med. 2012 Sep;53(9):1481-9
pubmed: 22851637
J Nucl Med. 2013 Mar;54(3):364-72
pubmed: 23297077
Neuroendocrinology. 2021;111(8):705-717
pubmed: 32721974
Clin Cancer Res. 2010 Feb 1;16(3):978-85
pubmed: 20103666
Radiology. 2000 Feb;214(2):483-90
pubmed: 10671597
J Nucl Med. 2006 Dec;47(12):2025-33
pubmed: 17138746
J Clin Endocrinol Metab. 1998 Jul;83(7):2417-20
pubmed: 9661621
J Nucl Med. 2018 Jun;59(6):909-914
pubmed: 29025985
Clin Nucl Med. 2020 Sep;45(9):e386-e392
pubmed: 32558709
J Nucl Med. 2011 Dec;52(12):1864-70
pubmed: 22072704
J Clin Endocrinol Metab. 2019 Dec 1;104(12):5843-5852
pubmed: 31298706
J Clin Endocrinol Metab. 2009 Nov;94(11):4398-405
pubmed: 19820010
Eur Radiol. 2016 Mar;26(3):900-9
pubmed: 26162577
Endocr Relat Cancer. 2017 Jul;24(7):R261-R274
pubmed: 28483790
J Nucl Med. 2011 Dec;52(12):1886-90
pubmed: 22068898
J Nucl Med. 2019 May;60(5):623-630
pubmed: 30291194
Future Oncol. 2014 Nov;10(14):2259-77
pubmed: 25471038
Virchows Arch. 2007 Aug;451 Suppl 1:S47-50
pubmed: 17684767
J Nucl Med. 2020 Apr;61(4):520-526
pubmed: 31519804
Cancer Res. 1997 Apr 1;57(7):1377-86
pubmed: 9102227
Endocr Rev. 2003 Aug;24(4):389-427
pubmed: 12920149
J Nucl Med. 2015 Jul;56(7):1075-8
pubmed: 25999434
Clin Cancer Res. 2019 Jan 15;25(2):584-594
pubmed: 30397175
J Nucl Med. 2017 Mar;58(3):451-457
pubmed: 27660147
Cancer Imaging. 2011 Jun 15;11:70-5
pubmed: 21697027
Neuroendocrinology. 2021;111(7):696-704
pubmed: 32580192
Oncotarget. 2015 Feb 20;6(5):3346-58
pubmed: 25671300
ScientificWorldJournal. 2014 Feb 13;2014:194123
pubmed: 24693229
J Nucl Med. 2020 Jun;61(6):890-896
pubmed: 31924723
Nucl Med Mol Imaging. 2018 Aug;52(4):254-265
pubmed: 30100938
J Nucl Med. 2019 Mar;60(3):386-392
pubmed: 30072500
Gastroenterology. 2007 May;132(6):2131-57
pubmed: 17498508
Endocr Rev. 2020 Apr 1;41(2):
pubmed: 31555796
Eur J Nucl Med Mol Imaging. 2003 May;30(5):781-93
pubmed: 12707737
Theranostics. 2017 Mar 1;7(5):1149-1158
pubmed: 28435454
Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2318-2327
pubmed: 30054698
J Nucl Med. 2019 Jun;60(6):801-805
pubmed: 30954939
Oncotarget. 2015 Sep 29;6(29):27566-79
pubmed: 26259237
Pancreas. 2020 Aug;49(7):863-881
pubmed: 32675783
J Radioanal Nucl Chem. 2017;313(2):279-289
pubmed: 28804185
Endocrine. 2012 Aug;42(1):80-7
pubmed: 22350660
Endokrynol Pol. 2016;67(1):68-71
pubmed: 26884118
Thyroid. 2015 Jun;25(6):567-610
pubmed: 25810047
J Nucl Med. 2011 Jul;52(7):1073-8
pubmed: 21680696
Neuroendocrinology. 2017 Mar 30;105(3):212-244
pubmed: 28355596
Neuroendocrinology. 2009;90(2):184-9
pubmed: 19713709
Pancreas. 2016 Feb;45(2):198-203
pubmed: 26390421
Eur J Radiol. 2016 Mar;85(3):680-7
pubmed: 26826888
Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2159-2169
pubmed: 29766245
Ann Nucl Med. 2018 Jan;32(1):7-15
pubmed: 28986764
Anticancer Res. 2017 Mar;37(3):1305-1311
pubmed: 28314296
J Nucl Med. 2012 Aug;53(8):1207-15
pubmed: 22782315
J Nucl Med. 2014 Feb;55(2):204-10
pubmed: 24379222